SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S ...
Q1 2026
May 12, 2026
FY 2025
Mar 19, 2026
Q4 2025
Q3 2025
Nov 12, 2025
Q2 2025
Aug 12, 2025